Skip to main content
. 2020 Aug 19;42(5):715–725. doi: 10.1038/s41401-020-0498-z

Fig. 5. GSK-3β knockdown attenuates the antifibrotic effects of the miR-99b-3p inhibitor.

Fig. 5

a Cultured CFs were transfected with GSK-3β siRNA (si-GSK-3β) or negative control (NC) for 48 h. The expression of GSK-3β and fibrotic markers were determined by Western blotting. b CFs with or without GSK-3β knockdown were treated with miR-99b-3p inhibitor and further stimulated with 100 nM Ang II for 48 h. Western blotting was performed to detect the protein levels of GSK-3β and fibrotic markers. c An EdU incorporation assay was used to examine the proliferation of CFs. d The migration ability of cells was tested by the scratch-wound assay. All data are presented as the mean ± SEM. *P < 0.05 vs. the NC or no treatment group, #P < 0.05 vs. the Ang II treatment group, $P < 0.05 vs. the Ang II plus miR-99b-3p inhibitor treatment group, n = 3.